Welcome to the official website of the SIPPET Study. This project was born a few years ago from the idea of Professor Pier Mannuccio Mannucci, who for many years dedicated to the scientific research in this field, supported by the Angelo Bianchi Bonomi Foundation in Milan, Italy.
The project involved 42 sites and 14 countries in 5 continents covering all race and ethnicities and has the ambitious purpose to definitively answer – for the first time through the scientific and objective approach of a randomized clinical trial – the contradictory findings that have arisen in years of observation in the clinical practice.
In particular, results show treatment of severe hemophilia A with recombinant factor VIII (rFVIII) is associated with an 87% higher incidence of inhibitors than treatment with plasma-derived factor VIII containing von Willebrand factor (pdFVIII/VWF) in previously untreated patients.
Results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) Study may have implications in the choice of products for treatment of patients with severe hemophilia A.
Statements of scientific organisations and patients associations
Statements from Regulators
Publications on SIPPET population
Publications on SIPPET results
» NEJM 2016: Commentary from Donna M. DiMichele
» Messori A, BMJ 2016
» Berntorp E, Hämostaseologie 2017
» Aledort L et al, J Thromb Haemost 2016
» Burnouf T and Strengers PFW, J Thromb Haemost 2016
» Fischer K and Blatny J. Haemophilia 2017
» van den Berg HM et al, Haemophilia 2017
» Warren B et al, American Academy of Pediatrics 2016